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Abstract
Background: Renal allograft recipients are reported to have a higher incidence of malignancy than the general
population. This single hospital-based study examined the incidence and clinicopathologic behavior of uterine
cervical carcinoma in renal transplant recipients.
Methods: Among 453 women receiving renal transplantation from January 1990 to December 2008, 5 patients
were diagnosed with cervical carcinoma. Medical records of these 5 patients were retrospectively reviewed, and
clinicopathologic data were collected and analyzed.
Results: The incidence of cervical carcinoma in renal transplant recipients was 58.1 out of 100,000 per year, which
is 3.5 times higher than in the general Korean population. The mean interval between the time of renal
transplantation and the time of cervical carcinoma diagnosis was 80.7 months. After a median follow-up of 96.2
months, there was no recurrence of the disease or death. In 4 patients who were positive from human
papillomavirus in situ hybridization (HPV ISH), high or probably high risk HPV DNA was detected in all. Punctate
staining of HPV ISH was detected in 3 out of 4 patients.
Conclusions: Higher incidence of cervical carcinoma is expected in renal transplant recipients, so appropriate
surveillance is needed to ensure early detection and treatment of cervical carcinoma.
Keywords: Cervical carcinoma, Renal transplantation, Human papillomavirus, Clinicopathologic behavior
Background
Recent advancements in immunosuppressive therapy
have reduced cases of acute rejection and improved the
long-term survival rate of grafts in organ transplant
patients. Long-term use of immunosuppressants has
likewise increased the incidence of infectious diseases,
autoimmune diseases, and malignancy in organ trans-
plant patients.
Particularly, the incidence of malignancy was reported
to be 2-31% in patients who had received renal trans-
plants [1-6], and was also reported to be a major cause of
one-third of cases of post-organ transplant death [7].
Possible mechanisms by which immunosuppressants
increase malignant carcinoma include the increased
chances of infection with such oncogenic viruses as the
human papillomavirus (HPV), DNA damage due to the
immunosuppresant, increased carcinogenicity of carcino-
gens due to the immunosuppressant, and immunologic
tolerance to oncocyte due to immunosuppresion [8,9].
HPV is known as the major cause of cervical carcinoma
and cervical intraepithelial neoplasia (CIN)[10,11]. More
than 100 types of HPV are known, and among these, 15
types are classified as high-risk HPV. Generally, most
HPV infections do not have symptoms and disappear
within 12 months of the onset of infection, although
high-risk HPV has been reported to be related to persis-
tent infection and the onset of CIN [12].
In the early stage of the developmental course of CIN
to invasive carcinoma, the phase at which the HPV DNA
integrates into the host’sD N Ah a sb e e nk n o w nt op l a y
an important role, although such developmental course
has yet to be clearly identified. It was reported that the
E2 gene loses its regulating function through this process,
a n dt h a ts u b s e q u e n to v e r - e x p r e s s i o no ft h eE 6a n dE 7
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multiple genes causes invasive cervical carcinoma [13].
Recent studies reported the usefulness of In Situ
Hybridization (ISH) for HPV, a method of testing
whether or not the HPV DNA, which has an important
role in early oncogenesis, is integrated into the host’s
DNA. It was also reported that when the HPV DNA
integrated into the host’s DNA, a punctate pattern
occurred in which obvious round spots were observable
in the nucleus. When unitegrated, the episomal HPV
DNA existed, and a diffuse pattern was observable in
which the nucleus was uniformly stained [13].
As described, immunosuppresants used after a renal
transplant to reduce the rejection reaction to graft may
increase the chances of opportunistic infection with
HPV, and the immunosuppressive condition itself may
also increase the risk of cervical carcinoma through
immunologic tolerance to oncocytes with accumulated
genetic variations [8,9].
In South Korea, statistical data on a national level on the
incidence of malignancy in patients who had received a
renal transplant are not available, and no proper screening
method for these patients has been established. As such,
this study was performed to investigate the incidence of
cervical carcinoma and other malignant carcinomas in
female patients who had received a renal transplant at a
single hospital, to analyze the clinicopathological features
of patients with cervical cancer and to analyze whether or
not the HPV DNA integrated into the host’sD N Aw i t h
the use of ISH.
Methods
This study was conducted according to the Declaration
of Helsinki, and approval was obtained from the Inter-
nal Review Board for the clinical trial. A total of 453
female patients who had received a renal transplant
from January 1990 to December 2008 at Kangnam St.
Mary’s Hospital of Catholic University were included in
the study. According to a retrospective review of the
medical charts of these patients, 36 of them had malig-
nancy. The incidence of carcinoma was analyzed
according to the type of carcinoma. The clinical factors
related to the renal transplant and the clinicopathologi-
cal factors related to cervical carcinoma were analyzed
based on the medical records of the five patients who
were diagnosed with cervical carcinoma. In addition, for
the HPV ISH and the analysis of the HPV type, a TMA
c o r ew i t has i z eo f5m m ,w h i c hi ss u f f i c i e n tf o ro b s e r -
vation, was prepared using the specimen from the uter-
ine cervix that was removed through hysterectomy.
Using the TMA of the uterine cervix, a 4 mm-thick
slice was prepared and attached to the coated slide, and
then used for the ISH [13].
HPV ISH of the uterine cervical tissue
T h eI n f o r mH P VI I I( V e n t a n a ,T u c s o n ,A Z ,U S A )p r o b e
that can identify 12 types of high-risk HPV(16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, and 66) was used. The HPV ISH
was performed using the BenchMark Automated Slide
Staining System (Ventana Medical System) according to
the manufacturer’s instructions. The result of the nuclear
staining was interpreted as positive, and the pattern of the
nuclear staining was classified as diffuse, punctated, and
mixed [13]. “Diffuse pattern” was defined as a pattern in
which the nucleus was diffusely but strongly stained
(Figure 1); and “punctated pattern,” as a pattern in which
the nucleus was stained, as if the nucleus was marked with
several obvious round dots (Figure 2).
HPV typing
The paraffin block, in which the patient’s tissue was
stored, was deparaffined, and the DNA was extracted
[14]. Subsequently, HPV typing was performed using
the commercial GoodgeneHPVchip (Goodgene Inc.,
Seoul, Korea), an HPV DNA chip, according to the
manufacturer’s instructions.
In brief, this genotyping was for a microarray system
that included probes of 40 types of HPV [14 types of
high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, and 82), seven types of moderate or probably
high-risk HPV (26, 53, 66, 69, 70, and 73), 13 types of
low-risk HPV (6, 11, 34, 40, 42, 43, 44, 54, 55, 61, 62,
72, and 81), and nine other types of HPV (7, 10, 27, 30,
32, 57, 83, 84, and 91)][15]. The detection of one or
more of these types of HPV was expressed as positive.
Figure 1 HPV ISH. Diffuse signal pattern (H&E, × 400). presents the
ISH signals of HPV shown by Inform HPV III kit (Ventana Medical
System). The diffuse signal pattern indicated that signals are
condensed and uniformly packed in the nucleus.
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Incidence of malignancy after a renal transplant
A total of 453 female patients had received a renal
transplant from January 1990 to December 2008 at
Kangnam St. Mary’s Hospital. Of these, 36 patients
(7.9%) were found to have had malignancy during the
follow-up. The most common type of malignancy was
thyroid carcinoma followed by cervical carcinoma and
bladder carcinoma. (Table 1).
Clinicopathological analysis of cervical carcinoma that
developed after a renal transplant
The mean age at the time of the renal transplant was
30.8 years (25-41 years). Three of the five patients used
Cyclosporin as an immunosuppressant, and two
switched to Tacrolimus due to their acute rejection
reaction. The grafts were well-maintained in four of the
five patients, whereas in one patient, the graft lost its
function, which led to hemodialysis.
The mean period of the dialysis before the renal trans-
plant was 13.4 months (1-51 months) (Table 2). The
mean age at which a patient was diagnosed with cervical
carcinoma was 37.4 years (27-41 years). Thus, the time
of diagnosis of the cervical carcinoma from the renal
transplant was 80.7 months on the average (5.6-136.8
months). Three patients were diagnosed with squamous
cell carcinoma; one patient, with adenosquamous cell
carcinoma; and one patient, with adenocarcinoma. All
of them received surgical treatment. One patient with
la1 cervical carcinoma underwent extrafascial hysterect-
omy without node dissection; two patients with lb1 and
two patients with lb2, type III radical hysterectomy with
pelvic lymphadenectomy. In the four patients who
underwent pelvic lymphadenectomy, lymph node metas-
tasis was not observed, and no additional chemotherapy
or radiation therapy was performed. The mean follow-
up period after the diagnosis of the uterine cervical car-
cinoma was 93.2 months (18-190 months), during which
no death o or recurrence of disease occurred (Table 3).
Staining pattern analysis and HPV typing according to
the HPV ISH of the cervical tissue
According to the HPV ISH of tissues from five patients,
four patients (80%) tested positive for HPV. Punctate
staining pattern was observed in three (75%) of these
four patients, and one manifested the diffuse staining
pattern. According to the HPV typing, high-risk HPV
(types 16 or 58) was detected in three patients, and
probably high-risk HPV (type 66) was detected in one
patient (Table 4).
Discussion
Statistics from many developed countries show that the
overall incidence of malignancy in patients who had
received an organ transplant is about 2-4 times higher
than in the general population, and that skin cancer and
malignant lymphoma are the most common types of
carcinoma in such patients. Moreover, the incidence of
malignancy such as cervical carcinoma, malignant lym-
phoma, and Kaposi’s sarcoma, which are attributable to
a carcinogenic virus, are also higher than in the general
population [4,16-18]. However, the types of malignancy
that develop after an organ transplant reportedly vary by
country and region. In South Korea, some studies
reported skin cancer is most common in patients who
had received an organ transplant [19,20] whereas other
studies reported that cervical carcinoma is most com-
mon [21]. Although the incidence of malignant carcino-
mas such as cervical carcinoma, thyroid carcinoma,
stomach carcinoma, and colorectal carcinoma is higher
Figure 2 HPV ISH.P u n c t a t es i g n a lp a t t e r n( H & E ,×4 0 0 ) .p r e s e n t s
the ISH signals of HPV shown by Inform HPV III kit (Ventana Medical
System). The punctate signal pattern indicated that signals are dot-
like and sparsely distributed in the nucleus.
Table 1 Clinical manifestations of study population
(1990-2008)
Type of malignancy No. Incidence (%)
Thyroid carcinoma 7 1.6
Cervical carcinoma 5 1.1
Bladder carcinoma 5 1.1
Breast carcinoma 5 1.1
Malignant lymphoma 4 1.0
Hepatocellular carcinoma 2 0.4
Colorectal carcinoma 2 0.4
Non-melanocytic skin carcinoma 2 0.4
Kaposi’s sarcoma 1 0.2
Stomach carcinoma 1 0.2
Parathyroid carcinoma 1 0.2
Malignant thymoma 1 0.2
Total 36 7.9
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available. In this study, thyroid carcinoma is the most
common and the annual incidence of malignancy that
developed after an organ transplant was 418.2 out of
100,000 patients, about 1.7 times higher than the 246 in
100,000 South Korean women in the general population
[22]. Cervical carcinoma develops after a renal trans-
plant in 58.1 of 100,000 patients a year, 3.5 times higher
than that in normal South Korean women (16.4 of
100,000 women)[22]. (Table 1).
Factors that increased the incidence of malignancy
after the organ transplant were reported to be related to
t h ea g ea tt h et i m eo ft h eo r g a nt r a n s p l a n t ,t h es e x ,t h e
race, the type of immunosuppressant, a history of renal
disease that required a transplant, and the period during
which dialysis was performed prior to the renal trans-
plant. Such factors, however, varied by study [4,7,23-25].
A close examination of the results of many studies
showed that the incidence of malignancy after an organ
transplant was higher in patients who were older at the
time of the transplant [4,7,23-25] in men [4,7,23], in
whites [4,7], in patients who used Tacrolimus as an
immunosuppressant [7,23], in patients who received a
renal transplant due to non-diabetic nepropathy [4,7,23],
and in patients who underwent dialysis for three years
or more before the organ transplant. In contrast, the
risk of malignancy was lower in patients who were
younger at the time of the organ transplant; in women,
blacks, or Asians; in patients who used CD25 as an
immunosuppressant [24]; in patients who received a
renal transplant due to diabetic nephropathy; and in
patients who underwent dialysis for a shorter period. In
this study, as the patients with cervical carcinoma
received a renal transplant at a young age (mean age:
30.8 years, 25-41 years) due to an unknown cause or a
non-diabetic disease, the mean period of the dialysis
before the renal transplant was as short as 13.4 months
(1-51 months). Since there were only five patients, it
was difficult to analyze the factors that can increase the
incidence of cervical carcinoma after a renal transplant
(Table 2).
Based on some studies, malignancy that developed in
patients who received an organ transplant had a worse
prognosis than that which developed in the general
population [1,26,27], whereas others reported that it was
not related to a worse prognosis [28,29]. In this study,
surgical treatment was performed in five patients with
cervical carcinoma (one patient, extrafascial hysterect-
omy only; four patients, type III radical hysterectomy
and pelvic lymphadnectomy), but no additional che-
motherapy or radiation therapy was performed. Because
during the mean follow-up period of 93.2 months (18-
1 9 0m o n t h s ) ,n od e a t ho rr e c u r r e n c eo fd i s e a s ew a s
observed, it could not be concluded that the prognosis
of cervical carcinoma that developed after the renal
transplant was worse than that which developed in the
general population (Table 3).
The incidence of HPV infection after a renal trans-
plant was reported to be 15-45%[9,30-33]. It was also
reported that an increase in opportunistic infection
Table 2 Clinicopathologic characteristics of cervical cancer patients
Case No. Age
at the time of KT (years)
Original kidney
disease
Pre-KT treatment
(Duration, months)
Maintenance
immunosuppression
Donor
source
Graft status
(event)
1 41 Hypertensive nephropathy No dialysis CsA + steroid Living Survival
2 25 Unknown
(no pre-KT biopsy)
PD (12) Tacrolimus + MMF+ steroid Living Survival
(acute rejection)
3 31 Unknown HD (3) CsA + MMF + steroid Living Survival
4 28 Chronic glomerulonephritis HD (51) Tacrolimus + MMF + steroid Living Survival
(acute rejection)
5 29 IgA nephropathy HD (1) CsA + steroid Living Fail
KT, kidney transplantation; CsA, cyclosporin A; PD, peritoneal dialysis; MMF, mycophenolate mofetil; HD, hemodialysis.
Table 3 Clinicopathologic characteristics of cervical cancer patients
Case No. Age
at the time of
diagnosis
Histologic
type
Pathologic diagnosis
(or Clinical stage)
Treatment Interval between KT
and final diagnosis
(months)
Patient status
1 41 Adenosquamous Ib1 R/H with pelvic LN dissection 5.6 NED
2 27 LCNK, SCC Ia1 T/H 27.7 NED
3 41 Adenocarcinoma Ib2 R/H with pelvic LN dissection 124.9 NED
4 38 LCNK, SCC Ib2 R/H with pelvic LN dissection 118.6 NED
5 40 LCNK, SCC Ib1 R/H with pelvic LN dissection 136.8 NED
KT, kidney transplantation; R/H, radical hysterectomy; LN, lymph node; NED, no evidence of disease; LCNK, large cell nonkeratinizing; SCC, squamous cell
carcinoma; T/H, total hysterectomy.
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the incidence of cervical intraepithelial neoplasia by 14
times compared to that of the age-adjusted control
group [8]. Moreover, statistics from many developed
countries indicate that the age-adjusted risk of cervical
carcinoma developing after a renal transplant was 1.6-
5.7 times that in the control group [4,16-18]. Early
screening seems mandatory and screening methods have
been extensively applied in patients who received an
organ transplant. American and European societies of
renal transplants recommend Papanicolaou test and pel-
vic examination. Due to the high incidence of HPV
infection with low rate of cytologic alteration found at
Pap test in renal transplant recipients, HPV screening
test is also discussed as a primary screening method.
However, no appropriate screening method has been
established for these patients because little is known
about the rate of progression to cervical carcinoma and
t h et i m et op r o g r e s s i o ni nr e nal transplant recipients.
Large-scale randomized controlled trials on the effec-
tiveness of the cytologic examination and HPV testing
are needed [34-36].
The HPV ISH performed in this study is advantageous
because it directly investigates whether or not the HPV
DNA was integrated into the host’s DNA; a diffuse
staining pattern indicates episomal HPV; a punctate
staining pattern in the nucleus indicates that integration
occurred. Therefore, because it was reported that the
integration of the HPV DNA plays an important role in
the early stage of carcinogenesis, the appearance of the
punctate staining pattern by the HPV ISH significantly
increases as the cervical intraepithelial lesion progresses
and in the case of invasive cervical carcinoma [13,37,38].
In this study, the experiment procedure was standar-
dized using automatic equipment. Inform HPV III kit
(Ventana Medical System), a detection system that has
high sensitivity due to its increased signal strength, was
used.
13 Eighty percent of the cervical lesions tested posi-
tive for HPV by the HPV ISH. Of these HPV-positive
tissues, 75% had a punctate staining pattern, and 25%, a
diffuse staining pattern (Table 4), which are consistent
with the results of other studies [37,39].
The types of HPV that were detected in the cervical
carcinoma were high-risk HPV (types 16 or 58) in three
of four patients, and probably high-risk HPV (type 66)
in one patient (Table 4). This suggests a direct relation-
ship between high-risk HPV and infiltrating cervical
carcinoma.
Conclusions
In this study, the incidence of cervical carcinoma in
patients who had received a renal transplant at the
authors’ hospital increased by 3.5 times compared to the
general population. Based on this risk, it is suggested
that appropriate screening tools be required for women
who had received a renal transplant. Analysis of the
clinical factors related to cervical carcinoma that devel-
ops after a renal transplant and analysis of the prognosis
of such carcinoma are required, since there were only a
few cases in this study. It is considered that collection
and management of statistical data on patients who had
received a renal transplant should be performed at the
national level for more efficient analysis.
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